Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001213900-20-033693
Filing Date
2020-10-28
Accepted
2020-10-28 16:17:27
Documents
4
Effectiveness Date
2020-10-28

Document Format Files

Seq Description Document Type Size
1 DEFA14A ea129030-defa14a_actiniumph.htm DEFA14A 61714
2 GRAPHIC ex99-1_001.jpg GRAPHIC 15135
3 GRAPHIC ex99-1_002.jpg GRAPHIC 83605
4 GRAPHIC ex99-1_004.jpg GRAPHIC 1269
  Complete submission text file 0001213900-20-033693.txt   200996
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36374 | Film No.: 201268859
SIC: 2834 Pharmaceutical Preparations